CoverageForm 410-K10-Q8-K13D13G13F

FTII · Futuretech II Acquisition Corp. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemQ2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23
Revenue----------
Cost of Revenue----------
Gross Profit----------
R&D----------
SG&A$58.7K$373.8K-$287.1K$204.9K$230.9K-$249.3K$260.4K$141.1K
Total Operating Expenses$138.7K$453.8K-$367.1K$284.9K$310.9K-$329.3K$221.6K$93.3K
D&A----------
Operating Income($66.3K)($254.0K)-($79.5K)($1.8K)$225.4K-$392.0K($126.1K)($71.5K)
Interest Expense-$100.0K---$100.0K---$100.0K
Income Tax$14.4K$35.7K-$43.6K$42.6K$95.8K-$242.0K$291.6K$260.1K
Net Income($80.6K)($289.7K)-($123.1K)($44.5K)$129.6K-$661.2K$836.4K$807.3K
EPS - Basic----------
EPS - Diluted----------

Balance Sheet

Line itemQ2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23
Cash & Equivalents$160.7K$130.6K$56.8K$1.9K$476$413$17.6K$5.5K$48.8K$150.3K
Accounts Receivable----------
Inventory----------
Accounts Payable----------
Current Assets$1.45M$2.05M$1.67M$1.56M$795.4K$754.8K$938.5K$710.7K$687.6K$423.9K
Total Assets$10.58M$11.07M$28.12M$28.50M$27.46M$26.98M$62.78M$61.36M$124.21M$121.84M
Current Liabilities$6.93M$7.34M$24.44M$6.20M$2.63M$2.57M$2.12M$4.59M$3.88M$2.34M
Long-term Debt----------
Total Liabilities$10.38M$10.79M$27.89M$9.65M$6.08M$6.02M$5.57M$8.04M$7.33M$5.79M
Stockholders' Equity($9.58M)($9.37M)($8.85M)($7.76M)($3.83M)($3.90M)($3.33M)($6.26M)($4.84M)($4.55M)
Retained Earnings($9.58M)($9.37M)($8.86M)($7.76M)($3.83M)($3.90M)($3.33M)($6.26M)($4.84M)($4.55M)

Cash Flow

Line itemQ2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23
Operating Cash Flow-($453.2K)---($282.1K)---($112.5K)
Investing Cash Flow-$17.63M---$36.27M---($1.15M)
Financing Cash Flow-($17.10M)---($36.01M)---$1.15M
CapEx----------
Free Cash Flow----------

Ratios

MetricQ2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23Q3 '23Q2 '23Q1 '23
Profitability
Gross margin----------
Operating margin----------
EBITDA margin----------
Net margin----------
Free cash flow margin----------
FCF / Net income----------
R&D / Revenue----------
SG&A / Revenue----------
Effective tax rate-----42.5%-26.8%25.8%24.4%
Return on assets-0.8%-2.6%--0.4%-0.2%0.5%-1.1%0.7%0.7%
Return on equity0.8%3.1%-1.6%1.2%-3.3%--10.6%-17.3%-17.7%
Return on invested capital----------
Liquidity
Current ratio0.210.280.070.250.300.290.440.150.180.18
Quick ratio0.210.280.070.250.300.290.440.150.180.18
Cash ratio0.020.020.000.000.000.000.010.000.010.06
Leverage
Debt / Equity----------
Debt / Assets----------
Debt / EBITDA----------
Interest coverage--2.5x---2.3x----0.7x
Equity multiplier-1.10-1.18-3.18-3.67-7.17-6.92-18.87-9.80-25.66-26.77
Liabilities / Assets0.980.970.990.340.220.220.090.130.060.05
Efficiency
Asset turnover----------
Inventory turnover----------
Days sales outstanding----------
Days inventory outstanding----------
Days payable outstanding----------
Cash conversion cycle----------
Valuation
P / E----------
P / B----------
P / S----------
EV / EBITDA----------
Growth
Revenue growth (YoY)----------
Revenue CAGR (3y)----------
Revenue CAGR (5y)----------
Gross profit growth (YoY)----------
Operating income growth (YoY)-3560.7%---98.6%---43.1%23.4%
Net income growth (YoY)-81.4%-----83.9%-68.7%--
EPS growth (YoY)----------
EPS CAGR (3y)----------
EPS CAGR (5y)----------
FCF growth (YoY)----------
FCF CAGR (5y)----------
Book value growth (YoY)-150.4%-140.2%-166.2%-24.0%20.9%14.3%-3.0%-102.3%-63.5%-60.5%

Peer comparison

Same SIC group: Biological Products, (No Diagnostic Substances)

CompanyRevenue (last FY)Net marginROE
TWST---16.4%
AMGN$36.75B21.0%89.1%
RXRX$74.68M-863.4%-57.0%
MRNA$1.94B-145.2%-32.6%
DNA$170.16M-183.8%-61.5%

Comparing FutureTech II Acquisition Corp. against the 5 most active filers in the same SIC group.